COMBACTE-NET-EXPECT
Start Date:
August 2019
End Date:
May 2022
Duration:
30 months
ID-CARE Role:
Website:
Partner
Description
Title: EXtraintestinal Pathogenic Escherichia Coli Trial (EXPECT)
Design: EXPECT1 - prospective observational pilot study; EXPECT2- prospective epidemiological study
Primary Objective: to provide a large network for rapid evaluation of novel treatment strategies; to generate innovative trial designs to facilitate the registration of novel antibacterial agents; and to design and validate tests to support the diagnosis of patients, identify the most appropriate treatments, and monitor the patient’s response.
Secondary Objective(s):
EXPECT-1: to assess success factors and barriers for a future Phase 3 randomized controlled trial, where the efficacy of a new vaccine to prevent invasive ExPEC disease will be tested in community-dwelling adults.
EXPECT-2: To estimate the O-serotype distribution of ExPEC isolated from hospitalized patients aged 60 and older with invasive ExPEC disease, and to evaluate the clinical case definition and risk factors.
Partners
University of Utrecht - NETHERLANDS (Coordinator)
Arbeitsgemeinschaft für Osteosynthesefragen (AO) Documentation and Publishing Foundation Clinical Investigation and Documentation - SWITZERLAND
Astra-Zeneca - ITALY
IDIBAPS August Pi i Sunyer Biomedical Research Institute - SPAIN
Centre Hospitalier Régional Universitaire de Besançon - FRANCE
Centre Hospitalier de LIMOGES - FRANCE
Cliniques Universitaries San Luc - BELGIUM
Da Volterra - ITALY
Eberhard Karls Universität Tuebingen - GERMANY
Erasmus Universitair Medisch Centrum Rotterdam - NETHERLANDS
European Clinical Research Infrastructure Network - FRANCE
University of Zurich - SWITZERLAND
European Forum for Good Clinical Practice - BELGIUM
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - ITALY
Fundacion Privada Instituto de Salud Global Barcelona - SPAIN
GlaxoSmithKline - UK
Goethe University Frankfurt - GERMANY
Guadeloupe
Helmholtz Centre for Infection Research - GERMANY
Hôpitaux Universitaires de Genève - SWITZERLAND
INSERM Institut National de la Santé Et de la Recherche Médicale - FRANCE
Instituto Nacional De Saùde - PORTUGAL
Janssen Infectious Diseases –Diagnostics
Julius Center Research Program Infectious Diseases - NETHERLANDS
Lausanne University Hospital - SWITZERLAND
Linköping Universitet - SWEDEN
Medical Center –University of Freiburg - GERMANY
North Bristol National Health Service Trust - UK
Radboud University Nijmegen Medical Centre - NETHERLANDS
Servicio Andaluz de Salud - SPAIN
Servicio Madrileño de Salud - SPAIN
Tel-Aviv Sourasky Medical Center - ISRAEL
The Medicines Company Rempex
University Hospital of Cologne - GERMANY
University Medicine of the Ernst Moritz Arndt - GERMANY
University of Antwerp - BELGIUM
University of Athens Medical School - GREECE
University of Greifswald - Germany
University of Oxford - UK
University of Verona - ITALY
Université Claude Bernard Lyon 1 - FRANCE
Université Joseph Fourier - FRANCE
Sponsor
